Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 14, 2022 09:03 ET | Source: MediWound Ltd.

MediWound to Present at Upcoming Investor Conferences in February

YAVNE, Israel, Feb. 14, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and...
February 10, 2022 07:00 ET | Source: MediWound Ltd.

MediWound Announces Additional $9 Million in Funding from BARDA to Support NexoBrid BLA Resubmission and the Expanded Access Treatment Protocol

YAVNE, Israel, Feb. 10, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and...
January 24, 2022 06:00 ET | Source: MediWound Ltd.

MediWound Announces Positive Topline Results From Its U.S. Phase 2 Trial of EscharEx for Debridement of Chronic Wounds

Primary Endpoint Met with Highly Statistically Significant ResultsNo Observed Safety IssuesFinal Data Readout Expected in Second Quarter of 2022 YAVNE, Israel, Jan. 24, 2022 (GLOBE NEWSWIRE) --...
December 20, 2021 07:00 ET | Source: MediWound Ltd.

MediWound Announces Positive Initial Data from its U.S. Phase 2 Pharmacology Study of EscharEx Showing Effective and Rapid Debridement in Chronic and Hard to Heal Wounds

Data Demonstrate EscharEx Reduces Biofilm and Bacterial BurdenEscharEx is Shown to be Safe with No Observed Safety Issues YAVNE, Israel, Dec. 20, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:...
December 06, 2021 07:00 ET | Source: MediWound Ltd.

MediWound Completes Enrollment of its EscharEx U.S. Phase 2 Adaptive Design Study

YAVNE, Israel, Dec. 06, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for...
November 18, 2021 07:30 ET | Source: MediWound Ltd.

EMA Provides Regulatory Path for Pediatric Label Extension for NexoBrid

YAVNE, Israel, Nov. 18, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for...
November 16, 2021 07:00 ET | Source: MediWound Ltd.

MediWound Reports Third Quarter 2021 Financial Results

Third Quarter Revenues of $6.4 Million; Year-to-Date 2021 Revenues Increased 21% Clarity on Regulatory Pathway for Resubmission of NexoBrid BLA, Anticipated in Mid- 2022 EscharEx Phase 2...
November 04, 2021 08:00 ET | Source: MediWound Ltd.

MediWound to Report Third Quarter 2021 Financial Results and Host a Conference Call and Webcast on November 16, 2021

YAVNE, Israel, Nov. 04, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair...
October 04, 2021 07:30 ET | Source: MediWound Ltd.

MediWound Announces Peer-Reviewed Publication of EscharEx In-Vivo Head-to-Head Comparator Study in the Journal of Wound Care

YAVNE, Israel, Oct. 04, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair...
September 03, 2021 16:14 ET | Source: MediWound Ltd.

MediWound to Present at Upcoming Investor Conferences

YAVNE, Israel, Sept. 03, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for...